| Ytd | 287.43% | |
| 1y | 208.49% |
| Open | 26.71 | Prev Close | 26.83 | Low | 25.76 | High | 27.10 | Mkt Cap | 277.97M |
| Vol | 58.08K | Avg Vol | 94.88K | EPS | -3.10 | P/E | N/A | Forward P/E | -6.64 |
| Beta | 1.21 | Short Ratio | 0.83 | Inst. Own | 42.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 22.52 | 200-d Avg | 14.51 | 1yr Est | 3.10 |
Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's f
The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical re
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more co
Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently publ
Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a
The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical re
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises th
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Biodesix NASDAQ: BDSX reported second-quarter 2026 revenue growth of 34% year over year, supported b
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus E
Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.0
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagno
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock of
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagno
Shares of Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) have received an average rating of "Modera
Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating a
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so
Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's ana
HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy r
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. Whil
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnos
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. Whil
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.00
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.81) per share which beat the analyst consens
2026 Financial OutlookThe Company anticipates generating between $106-112 million in total revenue i
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.49) per share which beat the analyst consens
XOM: -1.5% | Trump 'Inclined' To Keep Exxon Mobil Out Of Venezuela: 'Didn't Like The
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster pres
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Ca
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(1.16) per share which beat the analyst consens
Biodesix (NASDAQ:BDSX) raises FY2025 sales outlook from $80.000 million-$85.000 million to $84.000 m